JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Начало・Списък с акции・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

301.71 1.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

294.94

Максимум

302.34

Ключови измерители
By Trading Economics
Приходи	-65M 186M
Продажби	-152M 1.1B
P/E Средно за сектора	131.842 67.147
EPS	1.25
Марж на печалбата	16.993
Служители	2,500
EBITDA	-152M 145M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+50.75% upside

Дивиденти
By Dow Jones
Следващи печалби	30.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.1B 41B
Предишно отваряне	300.39
Предишно затваряне	301.71

Настроения в новините

By Acuity

16%

84%

29 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

256.565 / 269.81 Подкрепа & съпротива

Alnylam Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.05.2026 г., 22:17 ч. UTC

Печалби

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4.05.2026 г., 23:47 ч. UTC

Печалби

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4.05.2026 г., 23:45 ч. UTC

Печалби

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4.05.2026 г., 23:45 ч. UTC

Печалби

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4.05.2026 г., 23:40 ч. UTC

Пазарно говорене

Gold Steady Amid Likely Technical Recovery -- Market Talk

4.05.2026 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

Regis: Jim Beyer To Be Chief Executive of Combined Company

4.05.2026 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4.05.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4.05.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4.05.2026 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4.05.2026 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Shareholders to Own About 51% of Combined Company

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Board Unanimously Endorsed, Supported Deal

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Deal Unanimously Recommended by Vault Board

4.05.2026 г., 22:39 ч. UTC

Придобивния, сливания и поглъщания

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4.05.2026 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Regis Resources to Acquire All Ordinary Shares in Vault

4.05.2026 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Regis Resources, Vault Minerals Agree to Merger of Equals

4.05.2026 г., 22:37 ч. UTC

Печалби

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4.05.2026 г., 22:26 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4.05.2026 г., 22:02 ч. UTC

Печалби

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4.05.2026 г., 22:00 ч. UTC

Пазарно говорене

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4.05.2026 г., 21:52 ч. UTC

Печалби

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4.05.2026 г., 21:50 ч. UTC

Печалби

Westpac: Some Sectors More Affected Than Others>WBC.AU

4.05.2026 г., 21:50 ч. UTC

Печалби

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4.05.2026 г., 21:49 ч. UTC

Печалби

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4.05.2026 г., 21:44 ч. UTC

Печалби

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4.05.2026 г., 21:44 ч. UTC

Печалби

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4.05.2026 г., 21:43 ч. UTC

Печалби

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4.05.2026 г., 21:41 ч. UTC

Печалби

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4.05.2026 г., 21:40 ч. UTC

Печалби

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Сравнение с други в отрасъла

Ценова промяна

Alnylam Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

50.75% нагоре

12-месечна прогноза

Среден 449.12 USD 50.75%

Висок 550 USD

Нисък 330 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Alnylam Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

20 ratings

Купи

Задържане

Продай

Според 20 анализатори, дали борсови рейтинги на Alnylam Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

256.565 / 269.81Подкрепа & съпротива

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

29 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.